Evidence map›Paper›PMID 42766066›Full record

ReviewCurrent diabetes reports2026

Role of Oxytocin in Obesity.

Amber L Williams, James E Blevins

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amber L WilliamsDepartment of Veterans Affairs Medical Center, VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Research-151, 1660 South Columbian Way, Seattle, WA, 98108, USA.
James E BlevinsDepartment of Veterans Affairs Medical Center, VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Research-151, 1660 South Columbian Way, Seattle, WA, 98108, USA. jeblevin@u.washington.edu.ORCID http://orcid.org/0000-0002-7587-0380

Funding

BLRD VA I01 BX004102U.S. Department of Veterans Affairs I01BX004102
6 · The paper itself

Abstract

purpose of reviewThis review will summarize the role of the hormone, oxytocin (OT), in the control of energy balance and glucose homeostasis in pre-clinical and clinical models and the role of sex in contributing to these effects. RECENT

findingsOT reduces intake of chow and highly palatable foods, including sucrose, high fat diet, and chocolate cookies, suggesting that it suppresses homeostatic and hedonic feeding. Chronic administration reduces body weight in diet-induced obese (DIO) rodent models. These effects occur through a selective reduction of fat mass while sparing lean mass. While OT has been found to elicit modest weight loss in a translational nonhuman primate (NHP) model, the effects of intranasal treatment of OT in humans with obesity have been mixed, highlighting the need to optimize dose, dose frequency and duration of administration and the need to develop longer-lasting OT analogs to increase compliance and to minimize off-target effects.

Indexed as

ObesityOxytocinAnimalsEatingEnergy MetabolismHumansWeight LossOxytocinBody weightEnergy expenditureFood intakeObesityOxytocin

Identifiers

PMID42766066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.